ORKA
Oruka Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$74.48
+3.55%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$72.40
From 52W high−34.14%
Volume812460.00
Market cap$4.93B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$72.40
From 52W high
−34.14%
Volume
812460.00
Market cap
$4.93B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−28.7x
P/E (TTM)
—
RSI (14)
36.1
MomentumView details →
1D Return
+3.55%
YTD Return
+148.40%
SummaryUpdated Jun 1, 2026
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biotechnology company founded to develop innovative monoclonal antibody treatments for inflammatory and immunological diseases. Based in Menlo Park, California, the company focuses specifically on developing therapies for psoriasis and other immune-mediated inflammatory conditions. As a pre-revenue biotech firm, Oruka is currently advancing its pipeline of experimental drugs through clinical trials, with its lead candidates being ORKA-001 and ORKA-002.
Similar companies
Latest newsMore news →
Oruka Therapeutics announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis, showing deepening responses without additional dosing after Week 4.27d agoBlackRock Inc. acquired a new minority stake in Oruka Therapeutics, Inc., purchasing 4,990,181 shares valued at approximately $474,916,000, representing about 8.27% ownership, as disclosed in a 13F filing.56d ago